A comparative cost-effectiveness analysis of mechanical and pharmacological VTE prophylaxis after lower limb arthroplasty in Australia.

Rafael Torrejon TorresRhodri SaundersKwok M Ho

Published in: Journal of orthopaedic surgery and research (2019)

Apixaban, IPC or a sequential/simultaneous combination of both is currently the most cost-effective VTE prophylaxis regimens. The choice between them is best guided by the relative VTE and bleeding risks of individual patients.

Keyphrases

venous thromboembolism
lower limb
end stage renal disease
atrial fibrillation
chronic kidney disease
ejection fraction
newly diagnosed
prognostic factors